Current approach to the treatment of achalasia

被引：28

作者：

Cheatham J.G. ^{[1
]}

Wong R.K.H. ^{[2
]}

机构：

[1] Walter Reed Army Medical Center, Gastroenterology Service, Department of Medicine, Washington, DC 20307, 6900 Georgia Avenue, NW

[2] Walter Reed Army Medical Center, National Naval Medical Center, Uniformed Services University of Health Sciences, Washington, DC 20307, 6900 Georgia Avenue, NW

来源：

Current Gastroenterology Reports | 2011年 / 13卷 / 3期

关键词：

Achalasia; Calcium channel blockers; Endoscopic botulinum toxin injection; Heller myotomy; Nitrates; Peroral endoscopic myotomy; Phosphodiesterase type 5 inhibitors; Pneumatic dilation; Self-expanding metal stents;

D O I：

10.1007/s11894-011-0190-z

中图分类号：

学科分类号：

摘要：

Achalasia is a primary esophageal motility disorder characterized by aperistalsis and incomplete or absent relaxation of the lower esophageal sphincter (LES). The cause of the disease remains elusive and there is no intervention that improves the esophageal body function. Currently, treatment options focus on palliation of symptoms by reducing the LES pressure. The most effective and well-tolerated treatments continue to be the laparoscopic Heller myotomy and endoscopic pneumatic dilation; however, newer techniques (eg, peroral endoscopic myotomy and self-expanding metal stents) show promise. Botulinum toxin and pharmacologic therapy are reserved for those who are unable to undergo more effective therapies. Treatment options should be tailored to the patient, using current predictors of outcome such as the patient's age and post-treatment LES pressures. The aim of this article is to highlight current literature and provide an up-to-date approach to the treatment of achalasia. © 2011 Springer Science+Business Media, LLC.

引用

页码：219 / 225

页数：6

共 38 条

[1]

Mayberry J.F., Epidemiology and demographics of achalasia, Gastrointest Endosc Clin N Am, 11, 2, (2001)

[2]

Leeuwenburgh I., Scholten P., Alderliesten J., Et al., Long-term esophageal cancer risk in patients with primary achalasia: A prospective study, Am J Gastroenterol, 105, 10, pp. 2144-2149, (2010)

[3]

Bortolotti M., Medical therapy of achalasia: A benefit reserved for few, Digestion, 60, 1, pp. 11-16, (1999)

[4]

Gelfond M., Rozen P., Gilat T., Isosorbide dinitrate and nifedipine treatment of achalasia: A clinical, manometric and radionuclide evaluation, Gastroenterology, 83, 5, pp. 963-969, (1982)

[5]

Bortolotti M., Mari C., Lopilato C., Porrazzo G., Miglioli M., Effects of sildenafil on esophageal motility of patients with idiopathic achalasia, Gastroenterology, 118, 2, pp. 253-257, (2000)

[6]

Eherer A.J., Schwetz I., Hammer H.F., Petnehazy T., Scheidl S.J., Weber K., Krejs G.J., Effect of sildenafil on oesophageal motor function in healthy subjects and patients with oesophageal motor disorders, Gut, 50, 6, pp. 758-764, (2002)

[7]

Pasricha P.J., Ravich W.J., Hendrix T.R., Et al., Intrasphincteric botulinum toxin for the treatment of achalasia, N Engl J Med, 332, 12, pp. 774-778, (1995)

[8]

Pasricha P.J., Rai R., Ravich W.J., Hendrix T.R., Kalloo A.N., Botulinum toxin for achalasia: Long-term outcome and predictors of response, Gastroenterology, 110, 5, pp. 1410-1415, (1996)

[9]

Annese V., Bassotti G., Coccia G., Dinelli M., D'Onofrio V., Gatto G., Leandro G., Repici A., Testoni P.A., Andriulli A., A multicentre randomised study of intrasphincteric botulinum toxin in patients with oesophageal achalasia, Gut, 46, 5, pp. 597-600, (2000)

[10]

Kolbasnik J., Waterfall W.E., Fachnie B., Et al., Long-term efficacy of Botulinum toxin in classical achalasia: A prospective study, Am J Gastroenterol, 94, 12, pp. 3434-3439, (1999)

← 1 2 3 4 →